BioPharmSignal logoBioPharmSignal

Biotech News

Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights

Xeris Pharmaceuticals (XERS)Xeris PharmaceuticalsEarnings

Total revenue increased 44% year-over-year to $107 million Recorlev net revenue increased 93% year-over-year to more than $71 million Raises full-year 2026 total revenue guidance to $395 million to $405 million Raises 2030 total revenue outlook to more than $1 billion, up from approximately $750

Related news

XERSXeris Pharmaceuticals2026-10-22 12:00 EST

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

ABOSAcumen Pharmaceuticals2026-10-26 11:00 EST

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

DNLIDenali Therapeutics2026-10-22 20:01 EST

Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

TSHATaysha Gene Therapies2026-11-05 13:00 EST

Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12

NBIXNeurocrine Biosciences2026-11-02 21:49 EST

Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results

CGTXCognition Therapeutics2026-11-02 12:30 EST

Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026

SUPNSupernus2026-10-29 20:05 EST

Supernus Announces Third Quarter 2026 Financial Results

PRAXPraxis Precision Medicines2026-10-27 20:01 EST

Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation

SUPNSupernus2026-10-19 12:30 EST

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

NBIXNeurocrine Biosciences2026-10-12 20:01 EST

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results

View all latest news

Xeris Pharmaceuticals

Specialty Biopharmaceutical Portfolio Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability. Endocrine Products Recorlev is an oral cortisol-synthesis inhibitor for endogenous hypercortisolemia in Cushing's syndrome....

Recent company news

XERSXeris Pharmaceuticals2026-11-05 12:00 EST

Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights

XERSXeris Pharmaceuticals2026-11-02 13:00 EST

Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors

XERSXeris Pharmaceuticals2026-10-22 12:00 EST

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

XERSXeris Pharmaceuticals2026-10-15 12:00 EST

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

XERSXeris Pharmaceuticals2026-10-02 21:00 EST

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Stock data

Close
13.08 USD
Market cap
1.04B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States